The FDA has approved FoundationOne CDx to be utilized as a companion diagnostic for the dual-action tablet of niraparib plus abiraterone acetate, which was approved for use in combination with prednisone in adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.
Related Keywords
, Foundationone Cdx , Janssen Akeega , Shelby Moneer , Drug Administration , Janssen Biotech Inc , Foundation Medicine , Prostate Cancer Working , Patient Programs , Janssen Biotech , Niraparib Plus Abiraterone Acetate , Adult Patients With Deleterious Or Suspected Brca Mutated Metastatic Castration Resistant Prostate Cancer , Mia Levy , D , Phd ,
comparemela.com © 2020. All Rights Reserved.